LONDON and CAMBRIDGE, MA--(Marketwire - Jul 24, 2012) - Quanticate, a leading global data-focused clinical research organization (CRO), today announced the addition of Sally Du Toit as VP of Pharmacovigilance and Chris Cramer as VP of Clinical Data Management to their management team.
"As Quanticate continues to expand, we saw the need to add additional experienced leadership to our Clinical Data Management and Pharmacovigilance groups," explained David Underwood, Quanticate CEO. "With imminent changes in Pharmacovigilance regulations, our recent partnerships with Medidata RAVE and Comprehend Clinical, the launch of our centralized service provision (CSP) solution, expansion of our India facility, the launch of a new corporate website and significant sales growth, 2012 has become an exciting year for us. The addition of Sally and Chris will be of great importance in shaping our service as we continue to grow."
Du Toit, who has joined Quanticate from her last role as Director of Pharmacovigilance at Aptiv Solutions, has 27 years industry experience including experience as a Deputy QPPV. Du Toit will lead an experienced team of staff to support the current and future needs of clients. Du Toit explains, "I am very pleased to be joining Quanticate at this stage in their development, and look forward to expanding a global Pharmacovigilance approach that meets the requirements of the forthcoming regulatory changes. Since 2012 will be a challenging year for the Pharmaceutical industry with significant changes in European pharmacovigilance regulations coming into effect this July, I will pay special attention to make sure our clients are kept abreast of the changes, ensuring their pharmacovigilance service remains compliant at all times." Du Toit has specific experience in device trials and post-market device vigilance, in addition to extensive experience in both clinical studies and post-marketing surveillance for drugs.
Cramer has joined Quanticate from PharmaNet, where she was responsible for European data management operations. She brings over 25 years experience in the CRO and pharmaceutical industries and specific knowledge within late phase trials and electronic data capture solutions. "Quanticate's recent launch of a centralized service provision (CSP) solution as a next generation approach to functional service provision (FSP), coupled with a data centralization and visualization tool, CliQ, offers a great opportunity for customers to gain faster access, and more insight, into their data. With data being the end product of expensive trials and developments, we feel that it is important that we help our customers get the most out of their data," explains Cramer. "With a focus on providing customer excellence and investment in meeting growth requirements through initiatives such as the recent expansion of the clinical data management team in India and investment in state of the art technologies, there are many interesting activities taking place. I am pleased to be able to help to lead these activities and to have joined Quanticate at such an exciting time."
Quanticate, headquartered in the UK and USA, is a leading global Clinical Research Organization (CRO) primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. Our team has a passion for excellence and provides high quality, efficient outsourcing solutions for companies who need additional capacity or who want to outsource certain activities in their entirety.
Clinical trial management and post-marketing services include scalable on-site and off-site clinical data management, biostatistics, clinical programming, PK/PD analysis, medical writing, pharmacovigilance and consultancy. Quanticate is the first CRO to introduce the Centralized Service Provision (CSP) approach to outsourcing supported by its data centralization and visualization tool, CliQ, for both single study and cross-study data analysis. Please visit the new website at www.quanticate.com for further information and access to white papers.